Therefore, GLP-1 has been extensively studied as a possible treatment of type 2 diabetes, and GLP-1 analogues and DPP-4 inhibitors are now widely in clinical use in these patients [7–11]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.